Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0345904 (
liver cancer
)
15,188
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
SYF2
, also known as p29/
NTC31
/
CBPIN
, encodes a nuclear protein that interacts with Cyclin D-type binding-protein 1.
SYF2
has been reported to be involved in pre-mRNA splicing and cell cycle regulation. In the present study, we observed that
SYF2
was obviously upregulated in
HCC
tumor tissues and cell lines, and its level was positively correlated with the tumor grade and Ki-67 expression, as well as poor prognosis of
HCC
. In vitro, using serum starvation-refeeding experiment, our results suggested that
SYF2
was upregulated in proliferating
HCC
cells, and was positive correlated with the expression of PCNA and Cyclin D1. In addition, depletion of
SYF2
decreased PCNA and Cyclin D1 levels. Accordingly, interference of
SYF2
resulted in cells cycle arrest at G1/S phase in Huh7
HCC
cells. Furthermore, we found that
SYF2
might interact with Cyclin D1 and could confer doxorubicin resistance in
HCC
cells. These findings revealed that
SYF2
might play a regulatory role in the proliferation of
HCC
cells. In summary,
SYF2
may be a novel prognostic marker and serve as a potential therapeutic target in
HCC
.
...
PMID:Overexpression of SYF2 correlates with enhanced cell growth and poor prognosis in human hepatocellular carcinoma. 2626 52